15-SORRENTO-Therapeutics-Logo-FINAL.png
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021
September 27, 2021 13:13 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Virtual Healthcare Conference. Dr Henry...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
June 11, 2021 16:11 ET | Sorrento Therapeutics, Inc.
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Dr. Henry Ji to Participate in the CEO Roundtable during WuXi Healthcare Forum 2021 on March 17, 2021
March 17, 2021 01:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: ...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
December 22, 2020 18:59 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
November 09, 2020 09:00 ET | Sorrento Therapeutics, Inc.
IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.These initial trials are...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
October 12, 2020 17:21 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET | Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform
September 14, 2020 06:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive license agreement with Mayo Clinic for a...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price
August 12, 2020 19:51 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s...